Online inquiry

IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ15857MR)

This product GTTS-WQ15857MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD19 gene. The antibody can be applied in Rheumatoid arthritis (RA), Systemic lupus erythematosus (SLE) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001178098.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 930
UniProt ID P15391
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ15857MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11751MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ13664MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ11142MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10657MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ392MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ6394MR IVTScrip™ mRNA-Anti-Factor IX substitute, CSL654(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CSL654
GTTS-WQ3838MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, BCD-054(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BCD-054
GTTS-WQ11405MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW